A clinical study on the combination of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer
- VernacularTitle:吉西他滨联合顺铂治疗晚期非小细胞肺癌临床研究
- Author:
Mei HOU
1
;
Hui LI
;
Meng QIU
;
Lu LI
;
Xi YAN
Author Information
1. 华西医科大学附属第一医院
- From:
Chinese Journal of Lung Cancer
2001;4(3):191-193
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and toxicity of the combination of gemcitabine and cisplatin in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods Forty-three patients with locally advanced (stage ⅢB) or metastatic (stage Ⅳ) NSCLC were enrolled into the study. The patients received gemcitabine 1*!000*!mg／m2 on day 1,8 and 15, and cisplatin 30*!mg／m2 on day 1-3 of the 28-day cycle; or gemcitabine 1*!200*!mg／m2 on day 1 and 8, cisplatin 30*!mg／m2 on day 1-3, administered in 21-day cycle. Results An objective response was obtained in 48.8％ of patients (one complete and 20 partial responses), whereas 13 patients had stable disease and 9 patients were progressive. The response rate was 62.5％ in patients with no prior chemotherapy, and the response rate of 31.6％ was achieved in patients who had been given prior treatment. Significant difference existed between the two groups (P＜0.05). The main toxicities were leukopenia and thrombocytopenia. Conclusion The combination of gemcitabine and cisplatin is a feasible, well-tolerated, and active scheme in the treatment of advanced NSCLC.
